Dancing with "death": P-methoxyamphetamine overdose and its acute management

Journal of Toxicology - Clinical Toxicology

Volumn 41, Issue 2, 2003, Pages 143-154

  Caldicott, David G E ^a,b   Edwards, Nicholas A ^a   Kruys, Amanda ^b   Kirkbride, K Paul ^c   Sims, D Noel ^c   Byard, Roger W ^c   Prior, Michael ^d   Irvine, Rod J ^b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c FORENSIC SCIENCE SA   (Australia)

^d INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

4 Methoxyamphetamine; Amphetamine; P methoxyamphetamine; P methoxymethamphetamine; PMA

Indexed keywords

'BLUE CAP'; 'BLUE DR DEATH'; 'DEATH'; 'DOUBLE STACKED SUPERMAN'; 'DR DEATH'; 'GREEN DIAMOND'; 'GREEN SPARKLE'; 'HAPPY FACE'; 'MACINTOSH GREEN'; 'MITSUBISHI BEIGE'; 'MITSUBISHI DOUBLE STACK'; 'PURPLE TP'; 'SNOWBALL'; 'SUPERMAN'; 'VERSACE'; 'WHITE CAP'; 'WHITE ROLEX'; 3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 METHOXYAMPHETAMINE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; DANTROLENE; DIURETIC AGENT; ESMOLOL; GLYCERYL TRINITRATE; HALOPERIDOL; HYPERTENSIVE FACTOR; ILLICIT DRUG; MESCALINE; MIDAZOLAM; N ETHYL 3,4 METHYLENEDIOXYAMPHETAMINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; PHENTOLAMINE; PHENYTOIN; THIOPENTAL;

ADULT; AGITATION; ARTICLE; ARTIFICIAL VENTILATION; AUSTRALIA; CANNULATION; CASE REPORT; CLINICAL FEATURE; DRUG FORMULATION; DRUG OVERDOSE; FEMALE; GLASGOW COMA SCALE; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPERTHERMIA; HYPOTENSION; HYPOVOLEMIA; MORBIDITY; MORTALITY; OXYGEN THERAPY; SEIZURE; SEROTONINERGIC SYSTEM; STOMACH LAVAGE; THERMOREGULATION; URINE LEVEL;

ACUTE DISEASE; ADULT; AMPHETAMINES; CHROMATOGRAPHY, GAS; FEMALE; GLASGOW COMA SCALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDAZOLAM; OVERDOSE; POISONING; SOUTH AUSTRALIA; SUBSTANCE-RELATED DISORDERS;

EID: 0037273148     PISSN: 07313810     EISSN: None     Source Type: Journal    
DOI: 10.1081/CLT-120019130     Document Type: Article

References (54)

1. Martin TL. Three cases of fatal paramethoxyamphetamine overdose. J Anal Toxicol 2001; 25(7):649-651.
2. Kalant H. The pharmacology and toxicology of "Ecstasy" (MDMA) and related drugs. CMAJ 2001; 165(7): 917-928.
3. Green AR, Cross AJ, Goodwin GM. Review of the pharmacology and clinical pharmacology of 3,4-methy-lenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology (Berl) 1995; 119(3):247-260.
4. Green AL, El Hait MA. P-Methoxyamphetamine, a potent reversible inhibitor of Type-A monoamine oxidase in vitro and in vivo. J Pharm Pharmacol 1980; 32(4):262-266.
5. Wu D, Otton SV, Inaba T, Kalow W, Sellers EM. Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 1997; 53(11):1605-1612.
6. Bach MV, Coutts RT, Baker GB. Involvement of CYP2D6 in the in vitro metabolism of amphetamine two n-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica 1999; 29(7):719-732.
7. Kaminskas LM, Irvine RJ, Callaghan PD, White JM, Kirkbride P. The contribution of the metabolite p-hydroxyamphetamine to the central actions of pmethoxyamphetamine. Psychopharmacology (Berl) 2002; 160(2):155-160.
8. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, Chu TY. The demethylenation of methylenedioxymethamphetamine ("Ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 1994; 47(7):1151-1156.
9. Kraner JC, McCoy DJ, Evans MA, Evans LE, Sweeney BJ. Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA). J Anal Toxicol 2001; 25(7):645-648.
10. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol Lett 2000; 112-113:133-142.
11. Kreth K, Kovar K, Schwab M, Zanger UM. Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem Pharmacol 2000; 59(12):1563-1571.
12. Shulgin A, Shulgin A. PIHKAL; A Chemical Love Story. Berkeley, USA: Transform Press, 1991.
13. Baselt RC. Disposition of toxic drugs and chemicals in man. 5th ed. Foster City, California: Chemical Toxicology Institute, 2000.
14. Felgate HE, Felgate PD, James RA, Sims DN, Vozzo DC. Recent paramethoxyamphetamine deaths. J Anal Toxicol 1998; 22(2):169-172.
15. Cimbura G. PMA deaths in ontario. Can Med Assoc J 1974; 110(11):1263-1267.
16. Katagi M, Tsuchihashi H. Update on clandestine amphetamines and their analogues recently seen in Japan. J Health Sci 2002; 48(1):14-21.
17. Glennon RA, Young R, Dukat M, Cheng Y. Initial characterization of PMMA as a discriminative stimulus. Pharmacol Biochem Behav 1997; 57(1-2):151-158.
18. Longo M, Humeniuk R, Christie P, Topp L, Ali R. SA Party Drugs Trends 2001. Findings from the Illicit Drugs Reporting System, Party Drugs Module. Report No.: Technical Report No. 131. University of New South Wales: National Drug and Alcohol Research Council; 2002.
19. Dillon, P. PMA-How Dangerous Was It? 2002.
20. Byard RW, James RA, Gilbert JD, Felgate PD. Another PMA-related fatality in adelaide. Med J Aust 1999; 170(3):139-140.
21. Kirkbride KP, Ward AD, Jenkins NF, Klass G, Coumbaros JC. Synthesis of 4-methyl-5-arylpyrimidines and 4-arylpyrimidines: route specific markers for the leuckardt preparation of amphetamine 4-methoxyamphetamine, and 4-methylthioamphetamine. Forensic Sci Int 2001; 115(1-2):53-67.
22. Hansson R. Letter to Kirkbride, K. P.
23. Dal Cason TA. A re-examination of the mono-methoxy positional ring isomers of amphetamine, methamphetamine and phenyl-2-propanone. Forensic Sci Int 2001; 119(2):168-194.
24. Coumbaros JC, Kirkbride KP, Klass G. Application of solid-phase microextraction to the profiling of an illicit drug: manufacturing impurities in illicit 4-methoxyamphetamine. J Forensic Sci 1999; 44(6):1237-1242.
25. Hegadoren KM, Martin-Iverson MT, Baker GB. Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine. Psychopharmacology (Berl) 1995; 118(3):295-304.
26. Matthews RT, Champney TH, Frye GD. Effects of (±)3,4-methylenedioxymethamphetamine (MDMA) on brain dopaminergic activity in rats. Pharmacol Biochem Behav 1989; 33(4):741-747.
27. Spanos LJ, Yamamoto BK. Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat. Pharmacol Biochem Behav 1989; 32(4):835-840.
28. Daws LC, Irvine RJ, Callaghan PD, Toop NP, White JM, Bochner F. Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24(6):955-977.
29. Westberg, L. Synthetic drug alert: EMCDDA warns national networks. Report No.: 25, Portugal; 2000. DrugNet Europe; http://www.ceis.it/focalpoint/Inglese/download/DrugNet25.pdf.
30. Brown C, Osterloh J. Multiple severe complications from recreational ingestion of MDMA ('Ecstasy'). J Am Med Assoc 1987; 258(6):780-781.
31. Hughes JC, McCabe M, Evans RJ. Intracranial haemorrhage associated with ingestion of 'Ecstasy'. Arch Emerg Med 1993; 10(4):372-374.
32. Manchanda S, Connolly MJ. Cerebral infarction in association with ecstasy abuse. Postgrad Med J 1993; 69(817):874-875.
33. Chadwick IS, Curry PD, Linsley A, Freemont AJ, Doran B. Ecstasy, 3-4 methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J R Soc Med 1991; 84(6):371.
34. Dowling GP, McDonough ET III, Bost RO. 'Eve' and 'Ecstasy' A report of five deaths associated with the use of MDEA and MDMA. J Am Med Assoc 1987; 257(12):1615-1617.
35. Campkin NT, Davies UM. Another death from ecstacy. J R Soc Med 1992; 85(1):61.
36. Suarez RV, Riemersma R. "Ecstasy" and sudden cardiac death. Am J Forensic Med Pathol 1988; 9(4):339-341.
37. Screaton GR, Singer M, Cairns HS, Thrasher A, Sarner M, Cohen SL. Hyperpyrexia and rhabdomyolysis after MDMA ("Ecstasy") abuse. Lancet 1992; 339(8794): 677-678.
38. Ling LH, Marchant C, Buckley NA, Prior M, Irvine RJ. Poisoning with the recreational drug paramethoxyamphetamine ("Death"). Med J Aust 2001; 174(9):453-455.
39. The Hallucinogen PMA; Dancing With Death. US Department of Justice; 2000 (Drug Intelligence Brief); http://www.usdoj.gov/dea/pubs/intel/20025intellbrief. pdf.
40. Voorspoels S, Coucke V, Schepens P. Paramethoxyamphetamine: first fatalities in belgium. TIAFT Bull 2001; 31(4):12-13.
41. Lora-Tamayo C, Tena T, Rodriguez A. Amphetamine derivative related deaths. Forensic Sci Int 1997; 85(2):149-157.
42. Lechowicz W, Chudzikiewicz E, Janowska E, Stanaszek R. Complex intoxication with p-methoxyamphetamine (PMA) and other phenylalkylamines. Z. Zagadnien Nauk Sadowych 2001; XLVIII:118-126.
43. Stimpfl T, Friedrich E, Vycudilik W. Fatal Intoxication with paramethoxyamphetamine (PMA) and paramethoxymetamphetamine (PMMA). TIAFT Conference Proceedings, 39th Annual International Meeting, August 26-30, Prague, Czech Republic, 2001.
44. Römhild W, Quednow B, Rosner P. Lethal PMA (p-methoxyamphetamine) and PMMA (p-methoxymetamphetamine) intoxication,). TIAFT Conference Proceedings, 39th Annual International Meeting, August 26-30, Prague, Czech Republic, 2001.
45. Byard RW, Gilbert J, James R, Lokan RJ. Amphetamine derivative fatalities in south australia-is "Ecstasy" the Culprit? Am J Forensic Med Pathol 1998; 19(3):261-265.
46. James RA, Dinan A. Hyperpyrexia associated with fatal paramethoxyamphetamine (PMA) abuse. Med Sci Law 1998; 38(1):83-85.
47. Byard RW, Rodger N, James RA, Kostakis C, Camilleri A. Death and paramethoxyamphetamine-an evolving problem. Med J Aust 2002; 176:496.
48. Hamilton W. Personal communication to Kirkbride, K. P., 2002.
49. Prolov T. Personal communication to Kirkbride, K. P., 2002
50. Denborough MA, Hopkinson KC. Dantrolene and "Ecstasy". Med J Aust 1997; 166(3):165-166.
51. Mechan AO, Esteban B, O'Shea E, Elliott JM, Colado MI, Green AR. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') to rats. Br J Pharmacol 2002; 135(1):170-180.
52. Logan AS, Stickle B, O'Keefe N, Hewitson H. Survival following 'Ecstasy' ingestion with a peak temperature of 42 degrees C. Anaesthesia 1993; 48(11):1017-1018.
53. Hall AP, Lyburn ID, Spears FD, Riley B. An unusual case of ecstasy poisoning. Intensive Care Med 1996; 22(7):670-671.
54. American Academy of Clinical Toxicology and European Association of Poisons Centers and Clinical Toxicologists. Position statement. J Toxicol Clin Toxicol 1997; 35:699-762.